Abstract:
This study aims to evaluate the efficacy and application of ulinastatin combined with dexamethasone in treating sepsis. A retrospective study was conducted in Nishtar Medical Hospital from 5th July 2021 to 5th July 2022. It included 80 patients divided into Group A and Group B, with 40 patients each. In Group A, patients were included who were administered dexamethasone monotherapy. In Group B, 40 patients were administered ulinastatin combined with dexamethasone. Adverse effects, treatment efficacy and a related score of both groups were analyzed. Serum inflammatory factors were measured using ELISA. After the treatment, APACHE II scores were 17.43±5.33 and 12.48±2.42 in Groups A and B, respectively. Similarly, SOFA scores were 7.78±2.43 and 5.28±1.32 points, respectively. The adverse effects were in 13 (32.5%) patients in Group A and in 4 (10%) patients in Group B. from the results of current analysis it can be concluded that a combination of Ulinastatin and dexamethasone effectively treats sepsis.